A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB–IVM1a Melanoma in Four European Countries

High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a)

(2019) Viola Franke et al.   INTERNATIONAL JOURNAL OF CANCER

Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience

(2019) Raphael J. Louie et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Correlates of response and outcomes with talimogene laherperpvec

(2019) Alice Y. Zhou et al.   JOURNAL OF SURGICAL ONCOLOGY

1343PReal life use of talimogene laherparepvec in melanoma in centers in Austria and Switzerland

(2019) C Hoeller et al.   ANNALS OF ONCOLOGY

Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size

(2019) Sabran J. Masoud et al.   ANNALS OF SURGICAL ONCOLOGY

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

(2018) Jason Chesney et al.   JOURNAL OF CLINICAL ONCOLOGY

Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey

(2018) Peter Mohr et al.   ADVANCES IN THERAPY

1246PDTalimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study

(2018) H Gogas et al.   ANNALS OF ONCOLOGY

Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience

(2018) Matthew C. Perez et al.   ANNALS OF SURGICAL ONCOLOGY

Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial

(2016) Robert H. I. Andtbacka et al.   ANNALS OF SURGICAL ONCOLOGY

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

(2016) Kevin Harrington et al.   OncoTargets and Therapy

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results

(2015) Tessa Kennedy-Martin et al.   Trials

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY